Opinion

Video

Surgical Considerations and Patient Selection for PDS With Ranibizumab

Author(s):

Margaret Chang, MD

Dr. Margaret Chang details the facility requirements for PDS implantation, the specialized training surgeons need, and crucial factors to consider for the surgical implantation of PDS.

  1. What facilities are required to implant the device, and what specific training does a surgeon need?
  2. What are the key considerations for the surgical implantation and subsequent refilling of the PDS?
  3. What are the major adverse effects associated with the PDS, and which patients are not suitable candidates for this delivery system?
  4. How does the PDS with ranibizumab fit into the treatment landscape that also includes highly durable agents such as faricimab and high-dose aflibercept?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image courtesy of New York Eye and Ear Infirmary of Mount Sinai) Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE
June 23rd 2025

Q&A: Kira Manusis, MD, on how the Center for Refractive Solutions is redefining patient care at NYEE

Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials
June 23rd 2025

Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials

© 2025 MJH Life Sciences

All rights reserved.